2020Expert Opinion on Orphan DrugsRequires access

Advances in non-surgical treatment for pediatric patients with short bowel syndrome

Danielle Wendel, Beatrice E. Ho, Tanyaporn Kaenkumchorn, Simon Horslen

Open publisher page 1 citations

Abstract

Introduction Short bowel syndrome (SBS) is the most common cause of intestinal failure resulting in the need for long-term parenteral nutrition. Treatment for SBS involves the close management of parenteral and enteral nutrition as well as central venous access to prevent complications while allowing time for the remaining intestine to undergo the process of adaptation.Areas covered This review highlights the current state of management and treatment of SBS. Parenteral and enteral management strategies are outlined with a review of the evidence regarding lipid management, prevention of intestinal failure associated liver disease, and promotion of intestinal adaptation. Central venous access management and the evidence for prevention of central line-associated blood stream infections are reviewed. The most common nutritional deficiencies and complications associated with SBS are discussed and treatment strategies covered. Several hormone analogues have recently been developed which have been shown to promote intestinal adaptation. The evidence for these new drugs is also outlined.Expert opinion Previous treatments for SBS focused on symptom management and complication prevention. While these remain important in the intestinal rehabilitation of patients with SBS, the introduction of promising new hormonal therapies has provided a way to augment the process of adaptation.

About this research paper

What this paper is about

Introduction Short bowel syndrome (SBS) is the most common cause of intestinal failure resulting in the need for long-term parenteral nutrition. Treatment for SBS involves the close management of parenteral and enteral nutrition as well as central venous access to prevent complications while allowing time for the remaining intestine to undergo the process of adaptation.Areas covered This review highlights the current state of management and treatment of SBS. Parenteral and enteral management strategies are outlined with a review of the evidence regarding lipid management, prevention of intestinal failure associated liver disease, and promotion of intestinal adaptation. Central venous access management and the evidence for prevention of central line-associated blood stream infections are reviewed. The most common nutritional deficiencies and complications associated with SBS are discussed and treatment strategies covered. Several hormone analogues have recently been developed which have been shown to promote intestinal adaptation. The evidence for these new drugs is also outlined.Expert opinion Previous treatments for SBS focused on symptom management and complication prevention. While these remain important in the intestinal rehabilitation of patients with SBS, the introduction of promising new hormonal therapies has provided a way to augment the process of adaptation.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Introduction Short bowel syndrome (SBS) is the most common cause of intestinal failure resulting in the need for long-term parenteral nutrition. Treatment for SBS involves the close management of parenteral and enteral nutrition as well as central venous access to prevent complications while allowing time for the remaining intestine to undergo the process of adaptation.Areas covered This review highlights the current state of management and treatment of SBS. Parenteral and enteral management strategies are outlined with a review of the evidence regarding lipid management, prevention of intestinal failure associated liver disease, and promotion of intestinal adaptation. Central venous access management and the evidence for prevention of central line-associated blood stream infections are reviewed. The most common nutritional deficiencies and complications associated with SBS are discussed and treatment strategies covered. Several hormone analogues have recently been developed which have been shown to promote intestinal adaptation. The evidence for these new drugs is also outlined.Expert opinion Previous treatments for SBS focused on symptom management and complication prevention. While these remain important in the intestinal rehabilitation of patients with SBS, the introduction of promising new hormonal therapies has provided a way to augment the process of adaptation.

Key concepts: Medicine, Short bowel syndrome, Parenteral nutrition, Intestinal failure, Intensive care medicine, Enteral administration, Disease, Complication

Related papers

Back to paper searchBrowse research topicsOriginal source
Advances in non-surgical treatment for pediatric patients with short bowel syndrome — Research Paper | ScholarLens